FDAnews
www.fdanews.com/articles/73919-sumitomo-conforma-conclude-agreement

SUMITOMO, CONFORMA CONCLUDE AGREEMENT

July 1, 2005

Sumitomo Pharmaceuticals announced on June 30 that it has signed a licensing agreement with Conforma Therapeutics for amrubicin hydrocholoride, Sumitomo Pharmaceuticals' proprietary antitumor agent. Established in 1999, Conforma Therapeutics is a San Diego-based venture company specialized in antitumor agents. Under the terms of the agreement, Conforma Therapeutics will receive the rights to develop and market amrubicin hydrocholoride in the US and Europe. Amrubicin hydrochloride is a totally synthesized anthracycline antitumor antibiotic.

Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=10421)